The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Feb-14
$156 million
Target:
Thiele Kaolin Company
Advised Thiele Kaolin Company, a miner and processor of kaolin clay, on a leveraged capitalization and repurchase of a 40% stock interest from Stora Enso Oyj
23-Jun-09
$155 million
Target:
Monogram Biosciences, Inc.
Acquiror:
Laboratory Corporation of America Holdings
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
06-Apr-10
$153 million
Target:
Virgin Money Holdings (UK) Limited
Acquiror:
W.L. Ross & Co. LLC
Advised Virgin Money Holdings (UK) Limited, Virgin Group’s financial services arm, on the structuring of an investment of £100m from WL Ross & Co.
30-Aug-10
$150 million
Target:
Windward Investment Management
Acquiror:
The Charles Schwab Corporation
Advised The Charles Schwab Corporation on its acquisition of Windward Investment Management, an investment advisory firm
27-Aug-09
$144 million
Target:
NYFIX, Inc.
Acquiror:
NYSE Euronext
Advised the Special Committee of the Board of Directors of NYFIX, Inc., a provider of electronic trading solutions, on its sale to NYSE Euronext
14-Apr-08
$143 million
Target:
Clayton Holdings, Inc.
Acquiror:
Greenfield Partners
Advised Greenfield Partners on its acquisition of Clayton Holdings, a leading due diligence and surveillance provider
18-Dec-13
$141 million
Target:
Open Colleges Australia Pty Ltd
Acquiror:
Apollo Education Group, Inc.
Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
22-Dec-06
$115 million
Target:
The 401(K) Company (a subsidiary of Nationwide Financial)
Acquiror:
The Charles Schwab Corporation
Advised The Charles Schwab Corporation on its acquisition of The 401(K) Company from Nationwide Financial. The 401(K) Company is a leading provider of defined contribution retirement administration services
25-May-17
$115 million
Target:
F+W Media
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the out-of-court restructuring of its c.$100 million term loan and a $15 million new money investment from existing lenders
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
08-May-13
$110 million
Target:
Healthcare Finance Group, LLC
Acquiror:
Fifth Street Finance Corp.
Advised Fifth Street Finance Corp., a specialty finance company with approximately $2 billion of assets under management, on the acquisition of Healthcare Finance Group, LLC, a specialty lender providing asset-based lending and term loan products to the healthcare industry
01-Jun-10
$109 million
Target:
AT&T Japan (an AT&T Inc. company)
Acquiror:
Internet Initiative Japan
Advised AT&T Inc., a premier communications holding company, on its sale of the domestic network outsourcing business of AT&T Japan, its Japanese enterprise unit, to Internet Initiative Japan, one of Japan's leading Internet-access and comprehensive network solutions providers
19-Apr-22
Pending
$107 million
Target:
Syrah Resources
Acquiror:
U.S. Department of Energy
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
19-Dec-12
$100 million
Target:
Thiele Kaolin Company
Advised Thiele Kaolin Company, a miner and processor of kaolin clay, on a range of strategic options, resulting in a leveraged recapitalization and special dividend
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
12-Dec-05
$83 million
Target:
Ibbotson Associates
Acquiror:
Morningstar Inc.
Advised Ibbotson Associates on its sale to Morningstar Inc. for $83 million
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
13-May-14
$80 million
Target:
Publications International, Ltd. Children’s Division
Acquiror:
Jiangsu Phoenix Publishing and Media Corporation Limited
Advised Publications International, a leading consumer book publisher, on the sale of its Children’s Division to Jiangsu Phoenix Publishing and Media Corporation Limited
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
04-May-12
$55 million
Target:
Armajaro Trading Limited
Acquiror:
International Finance Corporation
Advised Armajaro Trading Limited, a global soft commodity trading house and supply chain manager, on raising mezzanine capital from the International Finance Corporation, a unit of the World Bank
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research